Spots Global Cancer Trial Database for all, adult
Every month we try and update this database with for all, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | NCT05026229 | Precursor Cell ... Philadelphia-Po... ALL, Adult | dasatinib plus ... dasatinib plus ... | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | NCT03751709 | B-Cell Acute Ly... ALL, Adult B-ALL | Blinatumomab Haplo-Mismatche... | 18 Years - | Cedars-Sinai Medical Center | |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | NCT04482894 | Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic... | Palliative Care... | 18 Years - | University of Virginia | |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | NCT04722848 | Acute Lymphobla... ALL, Adult Philadelphia-Po... | Ponatinib + Bli... Chemotherapy + ... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | NCT03884829 | AML, Adult Myelodysplastic... ALL, Adult CML, Refractory CLL, Refractory | CYC140 | 18 Years - | Cyclacel Pharmaceuticals, Inc. | |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | NCT04482894 | Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic... | Palliative Care... | 18 Years - | University of Virginia | |
| A Study of BN104 in the Treatment of Acute Leukemia | NCT06052813 | ALL, Adult AML, Adult | BN104 | 18 Years - | BioNova Pharmaceuticals (Shanghai) LTD. | |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | NCT03884829 | AML, Adult Myelodysplastic... ALL, Adult CML, Refractory CLL, Refractory | CYC140 | 18 Years - | Cyclacel Pharmaceuticals, Inc. | |
| Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. | NCT03541083 | ALL, Adult | Blinatumomab | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | NCT05026229 | Precursor Cell ... Philadelphia-Po... ALL, Adult | dasatinib plus ... dasatinib plus ... | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | NCT05026229 | Precursor Cell ... Philadelphia-Po... ALL, Adult | dasatinib plus ... dasatinib plus ... | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| A Study of BN104 in the Treatment of Acute Leukemia | NCT06052813 | ALL, Adult AML, Adult | BN104 | 18 Years - | BioNova Pharmaceuticals (Shanghai) LTD. | |
| A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | NCT05024357 | Precursor Cell ... Philadelphia-Po... ALL, Adult | Dasatinib | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
